• MeSH
• lidé MeSH
• percepční nedoslýchavost * MeSH
• střední objem trombocytu * MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• dopisy MeSH
• komentáře MeSH
• práce podpořená grantem MeSH

• MeSH
• akutní koronární syndrom chirurgie   MeSH
• lidé MeSH
• střední objem trombocytu * MeSH
• Check Tag
• lidé MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• komentáře MeSH
• úvodníky MeSH

BCR/ABL-negative myeloproliferative neoplasms (MPNs) are considered to be acquired thrombophilic conditions. Persistently enhanced platelet activation has been described in polycythaemia vera and essential thrombocythaemia (ET), and shown to contribute to a higher risk of arterial and venous thrombotic complications. Recent studies have shown that mean platelet volume (MPV) and immature platelet fraction (IPF) can serve as useful markers of platelet activation and increased risk of thrombosis. The aim of the present study was to investigate the relationship between these parameters and thrombotic events in BCR/ABL-negative MPN. MPV values in patients with BCR/ABL-negative MPN were significantly higher than MPV values of healthy individuals (P < 0.001). No significant difference in MPV or IPF was observed between groups of patients with and without thrombotic complications (P = 0.441; P = 0.110); the difference in IPF values was close to the significance level for patients with ET (P = 0.073). Higher values of IPF were more frequently detected in patients with JAK2 V617F positivity (P = 0.030). These patients had higher MPV more frequently than others, and this difference was close to the significance level (P = 0.056). Further studies should validate the use of platelet parameters to identify patients at high risk.

• MeSH
• bcr-abl fúzové proteiny genetika   MeSH
• chinazoliny terapeutické užití   MeSH
• dospělí MeSH
• inhibitory agregace trombocytů terapeutické užití   MeSH
• Janus kinasa 2 genetika   MeSH
• lidé středního věku MeSH
• lidé MeSH
• mutace MeSH
• myeloproliferativní poruchy komplikace   diagnóza   genetika   MeSH
• rizikové faktory MeSH
• senioři MeSH
• střední objem trombocytu * MeSH
• studie případů a kontrol MeSH
• trombocyty * metabolismus   patologie   MeSH
• trombóza krev   farmakoterapie   etiologie   MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Názvy látek
• anagrelide MeSH Prohlížeč
• bcr-abl fúzové proteiny MeSH
• chinazoliny MeSH
• inhibitory agregace trombocytů MeSH
• Janus kinasa 2 MeSH

BACKGROUND: Rheohemapheresis (RHF) is a method that can stop the activity of the dry form of age-related macular degeneration (AMD). The pathophysiologic mechanisms are not well understood, and the effects of the RHF procedures extend beyond the time of the individual procedures. PATIENTS AND METHODS: We present the data for 46 patients with AMD treated with a series of 8 rheohemapheretic procedures. Blood count parameters were measured before the first and the last procedures. The clinical effect was judged by changes in the drusenoid pigment epithelium detachment (DPED) area before and after the rheopheretic sessions. RESULTS: Rheopheresis caused a decrease in hemoglobin (P<0.001), a decrease in leukocytes (P<0.034), and an increase in platelets (P<0.005). We found a negative correlation between the amount of platelets and their volume (P<0.001, Pearson correlation coefficient: -0.509). We identified the platelet/MPV ratio as a good predictor of the clinical outcome. Patients with a platelet/MPV ratio greater than 21.5 (before the last rheopheresis) had a significantly better outcome (P=0.003, sensitivity of 76.9% and specificity of 80%). CONCLUSION: Several basic blood count parameters after RHF can be concluded to significantly change, with some of those changes correlating with the clinical results (reduction of the DPED area).

• MeSH
• cytaferéza metody   MeSH
• krevní obraz MeSH
• leukocyty cytologie   MeSH
• lidé středního věku MeSH
• lidé MeSH
• makulární degenerace terapie   MeSH
• odchlípení sítnice diagnóza   patologie   terapie   MeSH
• retinální drúzy komplikace   terapie   MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• trombocyty cytologie   MeSH
• výsledek terapie MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH